Business context and reporting period
The supplied filing is a Form 10-Q for the quarter ended March 31, 2018, filed May 8, 2018. The filing identifies the registrant as Vital Therapies, Inc., not Immunic, Inc.; verify that this is the intended filing. Vital Therapies is a clinical-stage biotechnology company developing the ELAD cell-based bio-artificial liver system. It reported no revenue from planned principal operations.
Key financial metrics
Amounts are in millions of dollars except per-share data. The company had no product revenue, so revenue margins are not meaningful.
| Metric | Q1 2018 / March 31, 2018 | Prior comparable / December 31, 2017 |
|---|---|---|
| Research and development expense | $10.157 | $9.628 in Q1 2017 |
| General and administrative expense | $4.335 | $3.059 in Q1 2017 |
| Total operating expenses | $14.492 | $12.687 in Q1 2017 |
| Net loss | $14.388 | $12.602 in Q1 2017 |
| Net loss per share, basic and diluted | $0.34 | $0.39 in Q1 2017 |
| Cash and cash equivalents | $43.647 | $56.901 at December 31, 2017 |
| Total assets | $47.008 | $60.384 at December 31, 2017 |
| Total current liabilities | $9.666 | $10.281 at December 31, 2017 |
| Stockholders’ equity | $37.295 | $50.044 at December 31, 2017 |
| Accumulated deficit | $310.341 | $295.953 at December 31, 2017 |
Operating cash outflow was $13.074 million, versus $10.910 million in Q1 2017. Investing cash outflow was $0.150 million, versus $0.271 million. Financing cash outflow was $0.030 million; Q1 2017 financing inflow was $37.826 million, principally from a follow-on offering. No debt balance is separately presented in the reported balance sheet.
Material changes versus the prior comparable period
- Total operating expenses rose 14% year over year. R&D increased 5%, largely due to BLA-related consultants, compensation and manufacturing/laboratory supplies; lower clinical-site costs partly offset the increases.
- G&A increased 42%, primarily reflecting compensation and stock-based compensation associated with the new CEO, legal and patent costs, and corporate and investor-relations consultants.
- Net loss increased by $1.786 million. Loss per share improved to $0.34 from $0.39, while weighted-average shares increased to 42.369 million from 32.645 million.
- Cash declined $13.254 million during the quarter. The prior-year quarter included substantial equity financing proceeds; there were no common-stock issuance proceeds in Q1 2018.
Outlook, risks and unusual items
- Enrollment in the Phase 3 VTL-308 trial was completed in March 2018, with 151 subjects enrolled. Management anticipated topline results in Q3 2018, likely September. Positive results could support a BLA, but approval or a filing based on one trial is not assured.
- Management estimated that $43.6 million of cash would fund operations through Q1 2019, assuming limited BLA work and no significant commercial buildout. The company disclosed substantial doubt about its ability to continue as a going concern for one year from issuance of the statements and said it would need additional liquidity. No committed external funding source was identified.
- Funding needs depend heavily on VTL-308 results. Success would bring higher BLA and commercialization costs and likely require financing; an unsuccessful or inconclusive trial could prompt restructuring, asset sales, or liquidation. Additional capital may be unavailable or dilutive.
- The existing Form S-3 shelf registration was stated to expire May 26, 2018, with $112.5 million remaining available, including $62.2 million through the ATM. The company expected to file a replacement shelf.
- ELAD is the company’s sole product candidate. Its earlier Phase 3 VTI-208 trial failed to meet primary and secondary endpoints; VTL-308 is based in part on analyses of that trial. Clinical, regulatory, manufacturing, reimbursement and supplier risks remain significant.
- No material litigation was reported. Management said disclosure controls were effective and there was no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the registrant and filing are correct: the supplied document is Vital Therapies, Inc., despite the request metadata naming Immunic, Inc.
- Check the VTL-308 topline results, endpoint outcomes, safety findings and any regulatory feedback; the stated Q3 2018 timing was forward-looking.
- Assess the company’s actual cash runway, subsequent financing, dilution and any changes to going-concern disclosures.
- Verify the status and terms of the replacement shelf registration and any ATM or other securities issuance.
- Evaluate whether further trials, manufacturing changes or additional regulatory evidence would be required even if VTL-308 were positive.